News

The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Todd Arnedt, PhD. [LISTEN TIME: 18 minutes]

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

A retrospective study presented at CMSC 2026 found GLP-1 receptor agonist use in multiple sclerosis was associated with higher physical activity levels and improvements across several patient-reported symptom domains.

Three-year extension data presented at CMSC 2026 showed sustained suppression of MRI activity and low relapse rates with frexalimab in relapsing multiple sclerosis.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.

Joohi Jimenez-Shahed, MD, professor of neurology at Mount Sinai, commented on the evolving understanding of Tourette syndrome, persistent misconceptions, and emerging therapeutic and neuromodulation approaches for tic disorders.

New exon‑51 skipping therapy boosts dystrophin and patient strength, with upcoming trial readouts aiming to support accelerated FDA approval.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.

FACT, an ongoing trial, evaluates the efficacy of efgartigimod alfa injection versus high-dose intravenous methylprednisolone in a cohort patients with neuromyelitis optica spectrum disorder.

Preliminary phase 1a findings suggest the investigational tau aggregation inhibitor OLX-07010 demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers, supporting continued development in Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Amlenetug, a monoclonal antibody targeting aggregated α-synuclein, showed a nonsignificant slowing of clinical progression compared with placebo and was generally well tolerated in patients with MSA.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mitochondrial dysfunction in neurodegeneration!

New findings showed that treatment with ofatumumab lowered relapse risk compared with rituximab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed ongoing unmet needs in CIDP, diagnostic challenges, and emerging research efforts evaluating complement inhibition and biomarker-driven care approaches.

Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 22, 2026.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute discussed how structured cardiovascular rehabilitation may improve recovery outcomes, reduce mortality, and influence future Medicare coverage for poststroke care.

Mitzi Joi Williams, MD, is joined by movement disorder specialists Chantale Branson, MD, MSCR, FAAN, and Keisha Young, MD, PhD, to discuss the causes, evaluation, and management of tremor disorders.

A newly published analysis proposed a 4-point Tardive Dyskinesia Impact Scale (TDIS) threshold to interpret patient-reported improvement in patients living with tardive dyskinesia.

Wearable accelerometer metric 6M95C tracks Duchenne progression beyond walking loss, delivering effort‑independent, real‑world outcomes to strengthen late‑stage clinical trials.

Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.